national stem-cell therapy logo

Neurona Therapeutics’ Progress in Phase I/II Clinical Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Ep

Neurona Therapeutics logo

Neurona Therapeutics, a clinical-stage biotherapeutics company, recently announced the completion of enrollment for the first cohort in its ongoing Phase I/II clinical trial of NRTX-1001. This investigational allogeneic cell therapy is being developed to treat drug-resistant mesial temporal lobe epilepsy (MTLE). The first cohort consisted of five subjects who received a one-time dose of NRTX-1001, […]

Exciting Advancements in Epilepsy Treatment: Neurona Therapeutics’ Breakthrough Research

Neurona Therapeutics logo

Neurona Therapeutics, a pioneering biotherapeutics company, has recently unveiled groundbreaking research in the realm of regenerative cell therapy for neurological disorders. Their latest publication highlights the potential of a unique cell therapy approach to treat focal epilepsy, a condition that has long challenged the medical community due to its resistance to conventional drugs. Key Findings […]

Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data

Neurona Therapeutics logo

SAN FRANCISCO, Nov. 21, 2022 (GLOBE NEWSWIRE) — Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced that Cory R. Nicholas, Ph.D., Neurona’s president and chief executive officer, was invited to present an overview of Neurona’s regenerative cell therapy technology, proprietary manufacturing process, cell delivery system, and preclinical […]